Newly formed gene therapy company has genetic Parkinson’s disease in its sights
Replay, the genome writing company formed in July, has launched its third product company, Kaleibe, which will use HSV gene therapy to target genetic brain disorders.
Archives for December 19, 2022
Fresenius Kabi secures US FDA approval for its adalimumab biosimilar
Fresenius Kabi’s citrate-free biosimilar, Idacio (adalimumab-aacf) has been approved by the US FDA.